Position in ARDX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$8,057,122
-$9,915,950 QoQ
Shares Held
1,579,828
-47.3% QoQ
Ownership
0.634%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
#24
of 248 holders
Holding Since
Jun 2020
15 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARDX Over Time
Shares Held
Position Value (USD)
Derivatives in ARDX
reported options exposure · as of Sep 30, 2025CallValue
$289,275
CallShares
52,500
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names. ARDX ranks #5 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
637,994 | $24,690,367 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
38,698 | $11,649,258 | |
| 3 | CAPR |
Capricor Therapeutics, Inc.
|
427,321 | $10,289,889 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
601,972 | $8,132,641 | |
| 5 | ARDX |
Ardelyx, Inc.
This page
|
1,579,828 | $8,057,122 | |
| 6 | URGN |
UroGen Pharma Ltd.
|
212,775 | $7,830,120 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,311 | $6,115,243 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
112,129 | $5,690,546 |
All Filings in ARDX
Export CSV
19 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,057,122 | 1,579,828 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $17,973,072 | 3,000,513 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $9,460,550 | 1,622,736 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $498,655 | 90,500 | Shares | Sole | 2025-11-14 | |
| 2025-09-30 | $289,275 | 52,500 | Call | Sole | 2025-11-14 | |
| 2025-06-30 | $963,994 | 245,917 | Shares | Sole | 2025-08-14 | |
| 2024-12-31 | $2,944,149 | 580,700 | Call | Sole | 2025-02-14 | |
| 2024-09-30 | $1,860,300 | 270,000 | Call | Sole | 2024-11-14 | |
| 2024-09-30 | $2,069,976 | 300,432 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $800,354 | 108,010 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $1,962,634 | 268,854 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $9,915,164 | 1,599,220 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $6,246,353 | 1,530,969 | Shares | Sole | 2023-11-14 | |
| 2023-09-30 | $3,949,848 | 968,100 | Put | Sole | 2023-11-14 | |
| 2022-12-31 | $299,250 | 105,000 | Call | Sole | 2023-02-14 | |
| 2022-12-31 | $478,235 | 167,802 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $80,325 | 67,500 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $159,300 | 270,000 | Shares | Sole | 2022-08-15 | |
| 2020-06-30 | $207,600 | 30,000 | Call | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||